Serum aminotransferase level and the risk of hepatocellular carcinoma: A population-based cohort study in Japan

European Journal of Cancer Prevention

Volumn 18, Issue 1, 2009, Pages 26-32

  Ishiguro, Seiji ^a,b   Inoue, Manami ^a   Tanaka, Yasuhito ^c   Mizokami, Masashi ^c   Iwasaki, Motoki ^a   Tsugane, Shoichiro ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b Graduate School of Medicine and Pharmaceutical Sciences

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Alanine aminotransferase; Hepatitis virus; Hepatocellular carcinoma; Incidence; Prospective study

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CANCER RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE MARKER; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAZARD RATIO; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; JAPAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; VIRUS ETIOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS; HEPATITIS VIRUSES; HUMANS; INCIDENCE; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; POPULATION; RISK FACTORS; TRANSAMINASES;

EID: 58149233919     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3282fa9edd     Document Type: Article

References (30)

1. Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2002). Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 40:1656-1659.
2. Bacon BR (2002). Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36:S179-S184.
3. Bell SJ, Lau A, Thompson A, Watson KJ, Demediuk B, Shaw G, et al. (2005). Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol 32:122-127.
4. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM (2004). Obesity and hepatocellular carcinoma. Gastroenterology 127:S97-S103.
5. Clark JM, Diehl AM (2003). Nonalcoholic fatty liver disease: an under recognized cause of cryptogenic cirrhosis. JAMA 289:3000-3004.
6. Green RM, Flamm S (2002). AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123:1367-1384.
7. Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S (2000). A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523-1527.
8. Huo Tl, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, et a/. (1998). Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 28:231-236.
9. Inoue M, Yoshimi I, Sobue T, Tsugane S (2005). Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 97:293-300.
10. Iwasaki M, Otani T, Yamamoto S, Inoue M, Hanaoka T, Sobue T, Tsugane S (2003). Background characteristics of basic health examination participants: the JPHC Study Baseline Survey. J Epidemiol 13:216-225.
11. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E (2004). Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127:S17-S26.
12. Kunde SS, Lazenby AJ, Clements RH, Abrams GA (2005). Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42:650-656.
13. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923.
14. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS (2002). NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349-1354.
15. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al. (2001). Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 34:1000-1005.
16. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. (1998). Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27: 868-872.
17. Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, et al. (2005). A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 43:599-605.
18. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002). Cancer Incidence in Five Continents, vol. VIII. Lyon: International Agency for Research on Cancer.
19. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. (2000). Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 118:760-764.
20. Pradat P, Alberti A, Poynard T, Esteban Jl, Weiland O, Marcellin P, et al. (2002). Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 36:973-977.
21. Rockhill B, Newman B, Weinberg C (1998). Use and misuse of population attributable fractions. Am J Public Health 88:15-19.
22. Stata Corporation (2005). Stata Statistical Software VCS. Texas: Stata Corporation.
23. Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H, Stuver SO (2006). Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 119:192-195.
24. Tanaka H, Tsukuma H, Yamano H, Oshima A, Shibata H (2004). Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 112: 1075-1080.
25. Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, et al. (2002). Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virusassociated cirrhosis. Cancer 94:1787-1795.
26. Tsugane S, Sobue T (2001). Baseline survey of JPHC study design and participation rate. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol 11 :S24-S29.
27. World Health Organization (2000). International Classification of Diseases for Oncology, 3rd ed. Geneva: WHO.
28. Yoshizawa H (2002). Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 62 (Suppl 1):8-17.
29. Yu AS, Keeffe EB (2003). Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol 98:955-956.
30. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. (2004). Peginterferon atfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127:1724-1732.